Pharmafile Logo

Article: The Patient Abroad

April 2, 2015 |  

Published in Medical Marketing & Media March 2015

Approximately 11 million people were medical tourists in 2013, generating a market worth over $50 billion. While obtaining accurate data is challenging, estimates suggest the global medical tourism market is expanding by 25% each year.

Having grown up in the UK, where high-quality healthcare is available to all through the National Health Service, I hadn’t given the concept of medical tourism a great deal of thought before I moved to Asia. It would simply not have occurred to me to seek healthcare overseas for any other reason than if I happened to fall ill while traveling. 

I first became aware of the concept when reading rumors that Zimbabwe’s President Robert Mugabe was being treated in one of Singapore’s exclusive private hospitals – which happened to be just down the road from my apartment at the time. This led to much discussion among my peers about how much it would cost to be a medical tourist in Singapore. “High end” patients can expect to accrue bills of thousands of dollars. The most expensive “hospitel” (hospital hotel) penthouse suite (not room) in Singapore costs over $8,000 per night – and it does not include the additional costs of medical treatment. This particular establishment anticipates that at least half of its “guests” (not patients) will come from overseas.

Read the full article on Medical Marketing & Media »

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

The Next Billion Patients

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

Huge Untapped Growth Potential of ASEAN

Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.

The power of observation in gathering patient insights

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.

Market Insights Can Deliver a Better Patient Experience

Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...

Warehousing of HCV patients reaches new high

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.

Removing the Roadblocks to Effective Patient Treatment

How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...

Driving Earlier Diagnosis: A Case Study in Psoriatic Arthritis

Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.